Epigen vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epigen
Epigen is a member of the epidermal growth factor (EGF) family. It plays roles in skin regeneration and has been studied for wound healing and anti-aging applications.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Epigen | Exenatide |
|---|---|---|
| Mechanism | Binds to and activates the EGF receptor (EGFR), promoting cell proliferation, migration, and differentiation. Involved in skin homeostasis and repair processes. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Topical: Typically used at low concentrations (ppm to low %) in cosmetic formulations. Research applications vary. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Primarily topical application for skincare. Research may use other routes for systemic effects. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Topical use generally well-tolerated. Theoretical concerns about promoting cell proliferation. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |